Bacillus subtilis DE111 intake may improve blood lipids and endothelial function in healthy adults
In: Beneficial MicrobesSearch for other papers by R.E. Trotter in
Current site
Google Scholar
Search for other papers by A.R. Vazquez in
Current site
Google Scholar
Search for other papers by D.S. Grubb in
Current site
Google Scholar
Search for other papers by K.E. Freedman in
Current site
Google Scholar
Search for other papers by L.E. Grabos in
Current site
Google Scholar
Search for other papers by S. Jones in
Current site
Google Scholar
Search for other papers by C.L. Gentile in
Current site
Google Scholar
Search for other papers by C.L. Melby in
Current site
Google Scholar
Search for other papers by S.A. Johnson in
Current site
Google Scholar
Search for other papers by T.L. Weir in
Current site
Google Scholar
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide. By 2030 it is anticipated that CVD will claim the lives of more than 24 million people. Throughout the last decade, researchers have investigated the role of the gut microbiota in the development of CVD. Evidence exists for a positive correlation between Bifidobacterium and vascular function, glucose tolerance, and reduced systemic inflammation. Another probiotic species, Bacillus subtilis, has also been found to reduce cholesterol levels in human and animal models. In light of these data, we examined various measures of cardiovascular health after consumption of Bifidobacterium animalis subsp. lactis strain BL04, with and without a cocktail of Escherichia coli-targeting bacteriophages (marketed as PreforPro), Bacillus subtilis strain DE111 or a maltodextrin-based placebo in a healthy human population. In a randomised, double-blind, placebo-controlled 4-week intervention conducted in individuals 18 to 65 years of age with a body mass index of 20 to 34.9, we saw no significant changes in measured CVD parameters among individuals consuming B. lactis with or without bacteriophages. However, B. subtilis supplementation resulted in a significant reduction in total cholesterol relative to baseline measures (-8 mg/dl; P=0.04, confidence interval (CI): -13.40, -0.19), as well as non-high-density lipoprotein-cholesterol (-11 mg/dl; P=0.01, CI: -12.43, -2.07). In addition we observed trending improvements in endothelial function (P=0.05, CI: -0.003, 0.370) and in low-density lipoprotein-cholesterol (P=0.06, CI:-12.29, 0.2864). Strikingly, these effects were seen in a largely healthy population. These data suggest that B. subtilis supplementation may be beneficial for improving risk factors associated with CVD. Further studies in populations of older adults or those with dyslipidaemia and endothelial dysfunction is warranted.
-
Battson, M.L., Lee, D.M., Jarrell, D.K., Hou, S., Ecton, K.E., Weir, T.L. and Gentile, C.L., 2018a. Suppression of gut dysbiosis reverses Western diet-induced vascular dysfunction. American Journal of Physiology – Endocrinology and Metabolism 314: E468-E477. https://doi.org/10.1152/ajpendo.00187.2017
-
Battson, M.L., Lee, D.M., Weir, T.L. and Gentile, C.L., 2018b. The gut microbiota as a novel regulator of cardiovascular function and disease. Journal of Nutritional Biochemistry 56: 1-15. https://doi.org/10.1016/j.jnutbio.2017.12.010
-
Bernini, L.J., Simão, A.N.C., Alfieri, D.F., Lozovoy, M.A.B., Mari, N.L., De Souza, C.H.B., Dichi, I. and Costa, G.N., 2016. Beneficial effects of Bifidobacterium lactis on lipid profile and cytokines in patients with metabolic syndrome: a randomized trial. Effects of probiotics on metabolic syndrome. Nutrition 32: 716-719. https://doi.org/10.1016/j.nut.2015.11.001
-
Cani, P.D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A.M., Delzenne, N.M. and Burcelin, R., 2008. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57: 1470-1481. https://doi.org/10.2337/db07-1403
-
Cohen, J., 2013. Statistical power analysis for the behavioral sciences. Taylor and Francis, London, UK.
'Statistical power analysis for the behavioral sciences', ().
-
Febvre, H., Rao, S., Gindin, M., Goodwin, N., Finer, E., Vivanco, J., Lu, S., Manter, D., Wallace, T. and Weir, T., 2019. PHAGE study: effects of supplemental bacteriophage intake on inflammation and gut microbiota in healthy adults. Nutrients 11: 666. https://doi.org/10.3390/nu11030666
-
Fechner, A., Kiehntopf, M. and Jahreis, G., 2014. The formation of short-chain fatty acids is positively associated with the blood lipid-lowering effect of lupin kernel fiber in moderately hypercholesterolemic adults. Journal of Nutrition 144: 599-607. https://doi.org/10.3945/jn.113.186858
-
Ghoneim, M.A.M., Hassan, A.I., Mahmoud, M.G. and Asker, M.S., 2016. Effect of polysaccharide from Bacillus subtilis sp. on cardiovascular diseases and atherogenic indices in diabetic rats. BMC Complementary and Alternative Medicine 16: 112. https://doi.org/10.1186/s12906-016-1093-1
-
Gibson, G.R., Hutkins, R., Sanders, M.E., Prescott, S.L., Reimer, R.A., Salminen, S.J., Scott, K., Stanton, C., Swanson, K.S., Cani, P.D., Verbeke, K. and Reid, G., 2017. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nature Reviews Gastroenterology and Hepatology 14: 491-502. https://doi.org/10.1038/nrgastro.2017.75
-
Hanifi, A., Culpepper, T., Mai, V., Anand, A., Ford, A.L., Ukhanova, M., Christman, M., Tompkins, T.A. and Dahl, W.J., 2015. Evaluation of Bacillus subtilis R0179 on gastrointestinal viability and general wellness: a randomised, double-blind, placebo-controlled trial in healthy adults. Beneficial Microbes 6: 19-27. https://doi.org/10.3920/BM2014.0031
-
Hill, C., Guarner, F., Reid, G., Gibson, G.R., Merenstein, D.J., Pot, B., Morelli, L., Canani, R.B., Flint, H.J., Salminen, S., Calder, P.C. and Sanders, M.E. 2014. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nature Reviews Gastroenterology and Hepatology 11: 506-514. https://doi.org/10.1038/nrgastro.2014.66
-
Hitosugi, M., Hamada, K. and Misaka, K. 2015. Effects of Bacillus subtilis var. Natto products on symptoms caused by blood flow disturbance in female patients with lifestyle diseases. International Journal of General Medicine 2015: 41-46. https://doi.org/10.2147/IJGM.S76588
-
Johnson, S.A., Litwin, N.S. and Seals, D.R., 2019. Age-related vascular dysfunction: what registered dietitian nutritionists need to know. Practice Applications Professional Practice| 119: 1790-1796. https://doi.org/10.1016/j.jand.2019.03.016
-
Karlsson, F.H., Fåk, F., Nookaew, I., Tremaroli, V., Fagerberg, B., Petranovic, D., Bäckhed, F. and Nielsen, J., 2012. Symptomatic atherosclerosis is associated with an altered gut metagenome. Nature Communications 3: 1245. https://doi.org/10.1038/ncomms2266
-
Kelly, R.P., Millasseau, S.C., Ritter, J.M. and Chowienczyk, P.J., 2001. Vasoactive drugs influence aortic augmentation index independently of pulse-wave velocity in healthy men. Hypertension 37: 1429-1433. https://doi.org/10.1161/01.HYP.37.6.1429
-
Khalesi, S., Sun, J., Buys, N. and Jayasinghe, R., 2014. Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension 64: 897-903. https://doi.org/10.1161/hypertensionaha.114.03469
-
Koren, O., Spor, A., Felin, J., Fak, F., Stombaugh, J., Tremaroli, V., Behre, C.J., Knight, R., Fagerberg, B., Ley, R.E. and Backhed, F., 2011. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proceedings of the National Academy of Sciences of the USA 108, Suppl. 1: 4592-4598. https://doi.org/10.1073/pnas.1011383107
-
Kumar, M., Nagpal, R., Kumar, R., Hemalatha, R., Verma, V., Kumar, A., Chakraborty, C., Singh, B., Marotta, F., Jain, S. and Yadav, H. 2012. Cholesterol-lowering probiotics as potential biotherapeutics for metabolic diseases. Experimental Diabetes Research 2012: 902917. https://doi.org/10.1155/2012/902917
-
Litwin, N.S., Van Ark, H.J., Hartley, S.C., Michell, K.A., Vazquez, A.R., Fischer, E.K., Melby, C.L., Weir, T.L., Wei, Y., Rao, S., Hildreth, K.L., Seals, D.R., Pagliassotti, M.J. and Johnson, S.A., 2019. Impact of red beetroot juice on vascular endothelial function and cardiometabolic responses to a high-fat meal in middle-aged/older adults with overweight and obesity: a randomized, double-blind, placebo-controlled, crossover trial. Current Developments in Nutrition 3: 113. https://doi.org/10.1093/cdn/nzz113
-
Malik, M., Suboc, T.M., Tyagi, S., Salzman, N., Wang, J., Ying, R., Tanner, M.J., Kakarla, M., Baker, J.E. and Widlansky, M.E., 2018. Lactobacillus plantarum 299v supplementation improves vascular endothelial function and reduces inflammatory biomarkers in men with stable cronary artery disease. Circulation Research 123: 1091-1102. https://doi.org/10.1161/CIRCRESAHA.118.313565
-
Matsumoto, M., Kitada, Y. and Naito, Y., 2019. Endothelial function is improved by inducing microbial polyamine production in the gut: a randomized placebo-controlled trial. Nutrients 11: 1188. https://doi.org/10.3390/nu11051188
-
Mozaffarian, D. and Wu, J.H.Y., 2018. Flavonoids, dairy foods, and cardiovascular and metabolic health: a review of emerging biologic pathways. Circulation Research 122: 369-384. https://doi.org/10.1161/circresaha.117.309008
-
Rice, B.H., 2014. Dairy and cardiovascular disease: a review of recent observational research. Current Nutrition Reports 3: 130-138. https://doi.org/10.1007/s13668-014-0076-4
-
Sawilowsky, S.S., 2009. New effect size rules of thumb. Journal of Modern Applied Statistical Methods 8: 597-599. https://doi.org/10.22237/jmasm/1257035100
-
Schauf, S., Nakamura, N. and Castrillo, C., 2019. Effect of Calsporin® (Bacillus subtilis C-3102) addition to the diet on faecal quality and nutrient digestibility in healthy adult dogs. Journal of Applied Animal Nutrition 7: e3. https://doi.org/10.1017/jan.2019.2
-
Seo, K.-C., Kim, M.-J., Hong, S.-H., Cha, S.-Y., Noh, J.-S., Kim, M.-J. and Song, Y.-O., 2010. The hypocholesterolemic effects of soymilk fermented with Bacillus subtilis compared to soymilk with Cheonggukjang powder in apolipoprotein e knockout mice. Preventive Nutrition and Food Science 15: 83-87. https://doi.org/10.3746/jfn.2010.15.2.083
-
Szulińska, M., Łoniewski, I., Skrypnik, K., Sobieska, M., Korybalska, K., Suliburska, J. and Bogdański, P., 2018. Multispecies probiotic supplementation favorably affects vascular function and reduces arterial stiffness in obese postmenopausal women – a 12-week placebo-controlled and randomized clinical study. Nutrients 10: 1672. https://doi.org/10.3390/nu10111672
-
Xie, N., Cui, Y., Yin, Y.-N., Zhao, X., Yang, J.-W., Wang, Z.-G., Fu, N., Tang, Y., Wang, X.-H., Liu, X.-W., Wang, C.-L. and Lu, F.-G. 2011. Effects of two Lactobacillus strains on lipid metabolism and intestinal microflora in rats fed a high-cholesterol diet. BMC Complementary and Alternative Medicine 11: 53. https://doi.org/10.1186/1472-6882-11-53
-
Yelland, L.N., Sullivan, T.R., Voysey, M., Lee, K.J., Cook, J.A. and Forbes, A.B., 2015. Applying the intention-to-treat principle in practice: guidance on handling randomisation errors. Clinical Trials 12: 418-423. https://doi.org/10.1177/1740774515588097
-
Ziganshina, E.E., Sharifullina, D.M., Lozhkin, A.P., Khayrullin, R.N., Ignatyev, I.M. and Ziganshin, A.M. 2016. Bacterial communities associated with atherosclerotic plaques from Russian individuals with atherosclerosis. PLoS ONE 11: e0164836. https://doi.org/10.1371/journal.pone.0164836
-
Zouari, R., Ben Abdallah-Kolsi, R., Hamden, K., Feki, A.E., Chaabouni, K., Makni-Ayadi, F., Sallemi, F., Ellouze-Chaabouni, S. and Ghribi-Aydi, D., 2015. Assessment of the antidiabetic and antilipidemic properties of Bacillus subtilis spb1 biosurfactant in alloxan-induced diabetic rats: antidiabetic and antilipidemic properties of Bacillus subtilis SPB1 biosurfactant. Biopolymers 104: 764-774. https://doi.org/10.1002/bip.22705
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 0 | 0 | 0 |
| Full Text Views | 3315 | 577 | 47 |
| PDF Views & Downloads | 1758 | 548 | 35 |
Bacillus subtilis DE111 intake may improve blood lipids and endothelial function in healthy adults
In: Beneficial MicrobesSearch for other papers by R.E. Trotter in
Current site
Google Scholar
PubMed
Search for other papers by A.R. Vazquez in
Current site
Google Scholar
PubMed
Search for other papers by D.S. Grubb in
Current site
Google Scholar
PubMed
Search for other papers by K.E. Freedman in
Current site
Google Scholar
PubMed
Search for other papers by L.E. Grabos in
Current site
Google Scholar
PubMed
Search for other papers by S. Jones in
Current site
Google Scholar
PubMed
Search for other papers by C.L. Gentile in
Current site
Google Scholar
PubMed
Search for other papers by C.L. Melby in
Current site
Google Scholar
PubMed
Search for other papers by S.A. Johnson in
Current site
Google Scholar
PubMed
Search for other papers by T.L. Weir in
Current site
Google Scholar
PubMed
Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide. By 2030 it is anticipated that CVD will claim the lives of more than 24 million people. Throughout the last decade, researchers have investigated the role of the gut microbiota in the development of CVD. Evidence exists for a positive correlation between Bifidobacterium and vascular function, glucose tolerance, and reduced systemic inflammation. Another probiotic species, Bacillus subtilis, has also been found to reduce cholesterol levels in human and animal models. In light of these data, we examined various measures of cardiovascular health after consumption of Bifidobacterium animalis subsp. lactis strain BL04, with and without a cocktail of Escherichia coli-targeting bacteriophages (marketed as PreforPro), Bacillus subtilis strain DE111 or a maltodextrin-based placebo in a healthy human population. In a randomised, double-blind, placebo-controlled 4-week intervention conducted in individuals 18 to 65 years of age with a body mass index of 20 to 34.9, we saw no significant changes in measured CVD parameters among individuals consuming B. lactis with or without bacteriophages. However, B. subtilis supplementation resulted in a significant reduction in total cholesterol relative to baseline measures (-8 mg/dl; P=0.04, confidence interval (CI): -13.40, -0.19), as well as non-high-density lipoprotein-cholesterol (-11 mg/dl; P=0.01, CI: -12.43, -2.07). In addition we observed trending improvements in endothelial function (P=0.05, CI: -0.003, 0.370) and in low-density lipoprotein-cholesterol (P=0.06, CI:-12.29, 0.2864). Strikingly, these effects were seen in a largely healthy population. These data suggest that B. subtilis supplementation may be beneficial for improving risk factors associated with CVD. Further studies in populations of older adults or those with dyslipidaemia and endothelial dysfunction is warranted.
| All Time | Past 365 days | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 0 | 0 | 0 |
| Full Text Views | 3315 | 577 | 47 |
| PDF Views & Downloads | 1758 | 548 | 35 |
